MCID: INT002
MIFTS: 61

Intermittent Claudication

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 12 54 44 15 37 70
Charcot Disease 73 6
Amyotrophic Lateral Sclerosis 70
Charcot's Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
MeSH 44 D007383
SNOMED-CT 67 195312007
ICD10 32 I73.9
UMLS 70 C0002736 C0021775

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as charcot disease, is related to peripheral artery disease and angina pectoris, and has symptoms including seizures, tremor and polydipsia. An important gene associated with Intermittent Claudication is SELP (Selectin P), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Thrombin and Vorapaxar have been mentioned in the context of this disorder. Affiliated tissues include Placenta, bone marrow and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 73 Charcot-Marie-Tooth disease (CMT) is a hereditary motor and sensory neuropathy of the peripheral nervous... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 709)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 31.8 VWF VEGFA SELP IL6 CRP ANGPT2
2 angina pectoris 31.3 IL6 CRP ACE
3 ischemia 31.1 VEGFA TEK SELP ACE
4 coronary heart disease 1 31.0 SERPINE1 CRP ACE
5 arteries, anomalies of 30.9 VEGFA SERPINE1 IL6 CRP ALB ACE
6 lipid metabolism disorder 30.7 SERPINE1 IL6 CRP ACE
7 cerebrovascular disease 30.6 VWF SERPINE1 SELP IL6 F2 CRP
8 arteriosclerosis 30.6 SERPINE1 SERPINC1 SELP IL6 IL10 CRP
9 peripheral vascular disease 30.6 VWF VEGFA SERPINE1 SERPINC1 SELP PF4
10 polyarteritis nodosa 30.6 SELP IL6 CRP
11 carotid artery disease 30.6 SELP CRP ACE
12 proteinuria, chronic benign 30.3 VEGFA ALB ACE
13 generalized atherosclerosis 30.3 VWF SERPINE1 IL6 CRP ALB ACE
14 systolic heart failure 30.3 IL6 CRP ACE
15 vasculitis 30.2 VWF SELP IL6 CRP
16 pulmonary disease, chronic obstructive 30.2 IL6 IL10 CRP ALB ACE
17 compartment syndrome 30.2 SERPINC1 IL6 F2 CRP ALB
18 protein c deficiency 30.2 SERPINE1 SERPINC1 F2
19 chlamydia pneumonia 30.2 IL6 IL10 CRP
20 chlamydia 30.2 IL6 IL10 CRP
21 carotid stenosis 30.2 VWF VEGFA SELP IL10 CRP ACE
22 limb ischemia 30.1 VWF VEGFA TEK SERPINE1 PGF IL6
23 thrombophilia 30.1 VWF SERPINE1 SERPINC1 SELP PF4 F2
24 thrombophilia due to activated protein c resistance 30.1 VWF SERPINE1 SERPINC1 F2
25 atherosclerosis susceptibility 30.1 VWF VEGFA SERPINE1 SELP IL6 CRP
26 polycythemia 30.1 VEGFA SERPINC1 F2 ACE
27 amyloidosis 30.0 TNNT2 IL6 CRP ALB
28 takayasu arteritis 30.0 IL6 IL10 CRP
29 bone resorption disease 30.0 IL6 IGF1 CRP ALB
30 thrombophlebitis 30.0 VWF SERPINE1 SERPINC1 F2 CRP ALB
31 common cold 30.0 SELP IL6 IL10 ALB
32 bronchitis 30.0 IL6 IL10 CRP ALB
33 polycythemia vera 29.9 VWF SELP PF4 IL6 F2
34 thrombophilia due to thrombin defect 29.9 VWF SERPINE1 SERPINC1 PF4 F2
35 varicose veins 29.9 VWF VEGFA SERPINC1 IL6 F2
36 glucose intolerance 29.9 IL6 IGF1 CRP ALB ACE
37 coronary stenosis 29.8 VWF SERPINE1 IL6 CRP ALB ACE
38 congestive heart failure 29.8 VEGFA TNNT2 IL6 CRP ALB ACE
39 thrombosis 29.8 VWF SERPINE1 SERPINC1 SELP PF4 F2
40 glycogen storage disease 29.8 VWF IGF1 CRP ALB
41 aortic aneurysm, familial abdominal, 1 29.7 SERPINE1 SERPINC1 IL6 IL10 CRP ALB
42 hypothyroidism 29.7 VWF IGF1 CRP ALB ACE
43 nephrotic syndrome 29.6 SERPINC1 IL6 F2 CRP ALB ACE
44 antiphospholipid syndrome 29.6 VWF SERPINE1 SERPINC1 SELP PF4 F2
45 hemangioma 29.6 VWF VEGFA TEK IL6 F2 ANGPT2
46 exanthem 29.4 VEGFA IL6 IL10 F2 CRP ALB
47 peripheral nervous system disease 29.4 VEGFA IL6 IL10 IGF1 CRP ALB
48 intermediate coronary syndrome 29.3 VWF TNNT2 SERPINC1 SELP PF4 IL6
49 infective endocarditis 29.3 TNNT2 SERPINE1 PF4 IL6 F2 CRP
50 endocarditis 29.2 SERPINE1 SERPINC1 PF4 IL6 IL10 F2

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):


Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


seizures; tremor; polydipsia; fatigue; back pain; headache; syncope; cyanosis; edema; pain; chills; chronic pain; asthenia; sciatica; signs and symptoms; signs and symptoms, digestive; hot flushes; vertigo/dizziness; sleeplessness; signs and symptoms, respiratory; oral manifestations; eye manifestations; urological manifestations; hypertriglyceridemic waist; body temperature changes; skin manifestations; renal colic; mobility limitation; prodromal symptoms; medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 ACE ALB ANGPT2 COL18A1 CRP F2
2 homeostasis/metabolism MP:0005376 10.47 ACE ALB ANGPT2 COL18A1 CRP F2
3 growth/size/body region MP:0005378 10.34 ACE F2 IGF1 IL10 IL6 NT5E
4 hematopoietic system MP:0005397 10.32 ACE ANGPT2 IGF1 IL10 IL6 NT5E
5 immune system MP:0005387 10.32 ACE ALB ANGPT2 CRP F2 IGF1
6 mortality/aging MP:0010768 10.25 ACE ALB ANGPT2 F2 IGF1 IL10
7 integument MP:0010771 10.2 ANGPT2 F2 IGF1 IL10 IL6 NT5E
8 digestive/alimentary MP:0005381 10.14 ALB ANGPT2 F2 HTR2A IL10 IL6
9 muscle MP:0005369 10.07 ALB F2 HTR2A IGF1 IL10 IL6
10 liver/biliary system MP:0005370 10.03 ACE ALB IL10 IL6 SELP SERPINC1
11 nervous system MP:0003631 10.03 ACE COL18A1 F2 IGF1 IL10 IL6
12 neoplasm MP:0002006 9.97 ACE ALB COL18A1 IGF1 IL10 IL6
13 renal/urinary system MP:0005367 9.85 ACE ALB COL18A1 IGF1 IL6 NT5E
14 respiratory system MP:0005388 9.61 ANGPT2 F2 IGF1 IL10 IL6 PGF
15 vision/eye MP:0005391 9.32 ACE ANGPT2 COL18A1 IL10 IL6 PGF

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 406)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Vorapaxar Approved Phase 4 618385-01-6
3
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
4
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
5
Losartan Approved Phase 4 114798-26-4 3961
6
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
7
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
8
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
9
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
10
Ramipril Approved Phase 4 87333-19-5 5362129
11
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
12
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
13
Glucagon Approved Phase 4 16941-32-5
14
Liraglutide Approved Phase 4 204656-20-2 44147092
15
Metformin Approved Phase 4 657-24-9 4091 14219
16
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
17
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
18
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
19
Candesartan Experimental Phase 4 139481-59-7 2541
20 Phosphodiesterase Inhibitors Phase 4
21 Vasodilator Agents Phase 4
22 Anticonvulsants Phase 4
23 Psychotropic Drugs Phase 4
24 Anti-Anxiety Agents Phase 4
25 calcium heparin Phase 4
26 carnitine Phase 4
27 Pharmaceutical Solutions Phase 4
28 Hormone Antagonists Phase 4
29 Hormones Phase 4
30 Glucagon-Like Peptide 1 Phase 4
31 Incretins Phase 4
32 Brewer's Yeast Phase 4
33 insulin Phase 4
34 Insulin, Globin Zinc Phase 4
35 Hypoglycemic Agents Phase 4
36 Fibrinolytic Agents Phase 4
37 Adrenergic beta-Antagonists Phase 4
38 Angiotensin Receptor Antagonists Phase 4
39 Protective Agents Phase 4
40 Neuroprotective Agents Phase 4
41 Anti-Asthmatic Agents Phase 4
42 Respiratory System Agents Phase 4
43 Bronchodilator Agents Phase 4
44 Phosphodiesterase 3 Inhibitors Phase 4
45 Adrenergic alpha-Antagonists Phase 4
46 Giapreza Phase 4
47 Angiotensinogen Phase 4
48 diuretics Phase 4
49
Olmesartan medoxomil Phase 4 144689-63-4 130881
50 Antihypertensive Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 808)
# Name Status NCT ID Phase Drugs
1 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
2 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
3 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
4 Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis Unknown status NCT02842424 Phase 4 Ramipril
5 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
6 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
7 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
8 Prevalence of Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Prognostic Significance of Resistance to Aspirin Completed NCT00262561 Phase 4 Aspirin
9 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft. Multicenter Randomized Study of an Impregnated Knitted Polyester Prosthesis Vs. PTFE (Uni-Graft Vs Gore-Tex). Completed NCT00300690 Phase 4
10 A Double Blind, Randomised, Placebo Controlled Trial to Study the Clinical and Cost Effectiveness of the Angiotensin Converting Enzyme Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
11 A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
12 4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
13 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
14 Balloon Angioplasty vs. Primary Stenting of Femoropopliteal Arteries Using Self-Expandable Nitinol Stents - a Randomized Controlled Trial Completed NCT00715416 Phase 4
15 The Effect of Angioplasty in Peripheral Arterial Disease on Endothelial Function Completed NCT00660634 Phase 4
16 EXPAND Study - Self Expanding Nitinol Stent Versus PTA With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication. A Prospective, Multi-center, Randomized Clinical Trail With Follow-up Investigations at 1, 3, 6, and 12 Months. Completed NCT00906022 Phase 4
17 A Multicenter Prospective Randomized Controlled Clinical Trial to Evaluate the Effectiveness and Safety of the Aperius™ PercLID™ System Versus Standalone Decompressive Surgery in Degenerative Lumbar Spinal Stenosis With Neurogenic Intermittent Claudication Completed NCT00905359 Phase 4
18 A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication Completed NCT00887744 Phase 4
19 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
20 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
21 Liraglutide Efficacy and Action on Type 2 Diabetes With Peripheral Atherosclerotic intErmittent Claudication (LEADPACE STUDY): a Prospective, 24-week, Multicenter, Randomized, Controlled Clinical Study Recruiting NCT04146155 Phase 4 Liraglutide+standard-of-care treatment
22 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Terminated NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
23 Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR) Terminated NCT02374957 Phase 4 Cilostazol
24 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
25 Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
26 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion. A Prospective Randomized Trial Comparing Silverhawk™ Atherectomy to CryoPlasty® Therapy for Lower Extremity Claudication Withdrawn NCT00407940 Phase 4
27 Prospective Randomized Trial Comparing X-STOP® Interspinous Process Decompression® System Versus Laminectomy for Treatment of Neurogenic Intermittent Claudication Withdrawn NCT00558129 Phase 4
28 A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients Withdrawn NCT02121288 Phase 4 Ticagrelor;clopidogrel
29 Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
30 Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population Unknown status NCT03272802 Phase 2, Phase 3 Edaravone;Riluzole
31 Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study Unknown status NCT03548311 Phase 3 methylcobalamin;saline solution
32 A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
33 Autologous Bone Marrow-derived Mononuclear Cells for Therapeutic Arteriogenesis in Patients With Limb Ischemia A Double Blind, Placebo Controlled, Study in Diabetic and Non-diabetic Patients Unknown status NCT00539266 Phase 2, Phase 3
34 Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients Unknown status NCT00251849 Phase 3 Rifalazil
35 The Contribution of Inflammation and Insulin Resistance to Intermittent Claudication Completed NCT00153166 Phase 2, Phase 3 atorvastatin and pioglitazone;atorvastatin/placebo;pioglitazone/placebo;placebo/placebo
36 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
37 Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. Completed NCT00372879 Phase 3
38 Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
39 Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00349622 Phase 3 ceftriaxone
40 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
41 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
42 A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS Completed NCT00136110 Phase 3 Sodium Valproate
43 A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
44 A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis Completed NCT00021697 Phase 3 AVP-923
45 A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
46 A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner. Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
47 The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013 Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
48 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
49 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS: Open-Label Extension for Patients Completing Study 3119002 Completed NCT03948178 Phase 3 Levosimendan
50 An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 70 / NDF-RT 51 :


cilostazol
Pentoxifylline
Riluzole

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

40
Bone Marrow, Endothelial, Bone, Spinal Cord, Skeletal Muscle, Skin, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 5083)
# Title Authors PMID Year
1
Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. 61 54
15649725 2005
2
Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. 61 54
15033248 2004
3
Platelet activation is increased in peripheral arterial disease. 54 61
12844097 2003
4
Platelets' glycoproteins and their ligands in patients with intermittent claudication. 61 54
12865882 2003
5
Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. 54 61
11958389 2001
6
Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial. 61 54
11448424 2001
7
New treatment options in intermittent claudication: the US experience. 61 54
11355276 2001
8
Exercise increases soluble adhesion molecules ICAM-1 and VCAM-1 in patients with intermittent claudication. 54 61
11455059 2001
9
Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. 54 61
11028477 2000
10
Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 54 61
9423790 1997
11
Repeated exercise induces release of soluble P-selectin in patients with intermittent claudication. 61 54
9408015 1997
12
Randomized placebo-controlled, double-blind trial of ketanserin in treatment of intermittent claudication. 54 61
1752890 1991
13
Role of aorto(bi)femoral bypass in treatment of patients with critical limb threatening ischemia. 61
32507455 2021
14
What are the effects of different modes of exercise training for intermittent claudication? - A Cochrane Review summary with commentary. 61
33791815 2021
15
Quantifying the risk-adjusted hospital costs of postoperative complications after lower extremity bypass in patients with claudication. 61
32931872 2021
16
[Use of the ankle-brachial index in the detection of peripheral arterial disease of the lower extremities in general medicine]. 61
33642048 2021
17
Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. 61
32252582 2021
18
Nerve growth factor in muscle afferent neurons of peripheral artery disease and autonomic function. 61
33063730 2021
19
A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. 61
33161072 2021
20
The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. 61
32891803 2021
21
Satisfaction and Acceptability of Telemonitored Home-Based Exercise in Patients With Intermittent Claudication: Pragmatic Observational Pilot Study. 61
33749616 2021
22
Effects of intermittent claudication due to arterial disease on pain-free gait. 61
33721726 2021
23
Endovascular foreign body removal of a MynxGrip polyethylene glycol (PEG) sealant embolus using a cerebral stent retriever. 61
33646460 2021
24
Blunt popliteal artery injury following tibiofemoral trauma: vessel-first and bone-first strategy. 61
33743028 2021
25
Gait analysis in the elderly patients with lumbar spinal stenosis. 61
33452537 2021
26
Lumbar Spinal Stenosis and Potential Management With Prostaglandin E1 Analogs. 61
33065578 2021
27
A Case of Isolated Infragenicular Arterial Lesions Successfully Treated with Open Endarterectomy. 61
33786107 2021
28
Editor's Choice - A Cost Effectiveness Analysis of Outpatient versus Inpatient Hospitalisation for Lower Extremity Arterial Disease Endovascular Revascularisation in France: A Randomised Controlled Trial. 61
33414066 2021
29
Elective Endovascular Stent-graft Implantation for External Iliac Artery Injury Following Blunt Pelvic Trauma. 61
33692306 2021
30
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. 61
33152418 2021
31
Revascularization of Intermittent Claudicants Leads to More Chronic Limb Threatening Ischemia and Higher Amputation Rates. 61
33775749 2021
32
Use of the walking impairment questionnaire as a measure of functional assessment. 61
33661020 2021
33
Gait alterations in patient with intermittent claudication: Effect of unilateral vs bilateral ischemia. 61
33675152 2021
34
Location of ischemia and ischemic pain intensity affect spatiotemporal parameters and leg muscles activity during walking in patients with intermittent claudication. 61
33762658 2021
35
A novel model of chronic limb ischemia to therapeutically evaluate the angiogenic effects of drug candidates. 61
33481698 2021
36
Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing phoenix atherectomy. 61
32914347 2021
37
Do we have a unified consensus on antithrombotic management of PAD? 61
33739074 2021
38
Therapeutic Effects of Medication Use on Intermittent Claudication: A Network Meta-analysis. 61
33235027 2021
39
Intermittent claudication treatment patterns in the commercially insured non-Medicare population. 61
33548437 2021
40
Ultrasound therapy for treatment of lower extremity intermittent claudication. 61
33750572 2021
41
Association of Age with Mortality Rate after Femoropopliteal Endovascular Therapy for Intermittent Claudication. 61
33642442 2021
42
Tibial bypass in patients with intermittent claudication is associated with poor outcomes. 61
32707381 2021
43
Obturator nerve impingement caused by an osteophyte in the sacroiliac joint: A case report. 61
33644181 2021
44
Prevalence of Cognitive Impairment in Individuals with Vascular Surgical Pathology: a Systematic Review and Meta-Analysis. 61
33573912 2021
45
A health insurance claims analysis on the effect of female sex on long-term outcomes after peripheral endovascular interventions for symptomatic peripheral arterial occlusive disease. 61
33647437 2021
46
Editor's Choice - The GermanVasc Score: A Pragmatic Risk Score Predicts Five Year Amputation Free Survival in Patients with Peripheral Arterial Occlusive Disease. 61
33334671 2021
47
Sarcopenia as a Prognostic Factor in Peripheral Arterial Disease: Descriptive Review. 61
33556522 2021
48
Combined Exercise and Nutrition Optimization for Peripheral Arterial Disease: A Systematic Review. 61
33160056 2021
49
Optimal cut-off value of preprocedural geriatric nutritional risk index for predicting the clinical outcomes of patients undergoing endovascular revascularization for peripheral artery disease. 61
32888832 2021
50
A systematic review of the role of heat therapy for patients with intermittent claudication due to peripheral artery disease. 61
33587690 2021

Variations for Intermittent Claudication

Copy number variations for Intermittent Claudication from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107025 17 11200000 22100000 Microduplication Charcot

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

Pathways related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 VEGFA TEK PGF PF4 IL6 IL10
2
Show member pathways
13.43 VEGFA TEK PGF IL6 IL10 IGF1
3
Show member pathways
13.17 TEK PGF PF4 IL6 IL10 IGF1
4
Show member pathways
12.81 VWF VEGFA TEK PGF IL6 IGF1
5
Show member pathways
12.77 VWF VEGFA TEK SERPINE1 SERPINC1 SELP
6 12.65 VEGFA TEK PGF IGF1 ANGPT2
7
Show member pathways
12.61 VEGFA TEK PGF IGF1 ANGPT2
8
Show member pathways
12.44 TEK IL6 IL10 F2 ANGPT2
9
Show member pathways
12.19 SERPINE1 IL6 F2 CRP ALB
10
Show member pathways
12.12 TNNT2 IL6 IGF1 ACE
11
Show member pathways
12.05 TEK SELP PF4 F2 ANGPT2
12 12.03 VEGFA IL6 IL10 HTR2A
13
Show member pathways
11.97 VWF SERPINE1 SERPINC1 PF4 F2
14 11.96 VWF SERPINE1 SERPINC1 F2
15 11.78 VEGFA TNNT2 IL6 IGF1 ALB
16 11.56 VEGFA SERPINE1 NT5E
17 11.41 SELP IL6 IL10
18 11.3 VEGFA NT5E IL6 IGF1
19 11.22 VEGFA SERPINE1 ANGPT2
20 11.14 VEGFA TEK SERPINE1 IL6 IGF1 ANGPT2
21 10.66 TEK PGF PF4 IL6 IL10 IGF1

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 VWF VEGFA TEK SERPINE1 SERPINC1 PGF
2 collagen-containing extracellular matrix GO:0062023 9.8 VWF SERPINE1 SERPINC1 PF4 F2 COL18A1
3 endoplasmic reticulum lumen GO:0005788 9.72 SERPINC1 IL6 F2 COL18A1 ALB
4 platelet alpha granule lumen GO:0031093 9.63 VWF VEGFA SERPINE1 PF4 IGF1 ALB
5 extracellular space GO:0005615 9.53 VWF VEGFA SERPINE1 SERPINC1 SELP PGF

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.05 VEGFA PF4 IL6 IGF1 CRP
2 positive regulation of cell proliferation GO:0008284 10 VEGFA PGF IL6 IGF1 HTR2A F2
3 negative regulation of apoptotic process GO:0043066 9.99 VEGFA TEK IL6 IL10 IGF1 ALB
4 positive regulation of protein phosphorylation GO:0001934 9.93 VEGFA TEK PGF F2
5 leukocyte migration GO:0050900 9.92 TEK SELP F2 ANGPT2
6 response to hypoxia GO:0001666 9.9 VEGFA TEK PGF ANGPT2
7 cellular response to lipopolysaccharide GO:0071222 9.88 SERPINE1 PF4 IL6 IL10
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 VEGFA IL6 IGF1
9 hemostasis GO:0007599 9.78 VWF SERPINC1 F2
10 response to activity GO:0014823 9.77 IL6 IL10 ANGPT2
11 cellular protein metabolic process GO:0044267 9.77 SERPINC1 IL6 IGF1 F2 ALB
12 positive regulation of MAPK cascade GO:0043410 9.76 VEGFA TEK IL6 IGF1
13 platelet activation GO:0030168 9.73 VWF PF4 IL6 F2
14 acute-phase response GO:0006953 9.72 IL6 F2 CRP
15 negative regulation of endothelial cell apoptotic process GO:2000352 9.71 TEK SERPINE1 IL10
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.71 VEGFA IL6 IGF1 HTR2A
17 positive regulation of JAK-STAT cascade GO:0046427 9.67 IL6 IL10 F2
18 negative regulation of fibrinolysis GO:0051918 9.65 SERPINE1 F2
19 sprouting angiogenesis GO:0002040 9.65 VEGFA TEK PGF
20 positive regulation of angiogenesis GO:0045766 9.65 VEGFA TEK SERPINE1 PGF ANGPT2
21 neutrophil mediated immunity GO:0002446 9.64 IL6 ACE
22 negative regulation of lipid storage GO:0010888 9.63 IL6 CRP
23 angiogenesis GO:0001525 9.63 VEGFA TEK SERPINE1 PGF COL18A1 ANGPT2
24 positive regulation of mast cell chemotaxis GO:0060754 9.62 VEGFA PGF
25 positive regulation of endothelial cell proliferation GO:0001938 9.62 VEGFA TEK PGF IL10
26 negative regulation of MHC class II biosynthetic process GO:0045347 9.61 PF4 IL10
27 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.58 VEGFA ACE
28 glomerulus vasculature development GO:0072012 9.57 TEK ANGPT2
29 Tie signaling pathway GO:0048014 9.56 TEK ANGPT2
30 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.35 VEGFA TEK SELP IGF1 F2
31 platelet degranulation GO:0002576 9.17 VWF VEGFA SERPINE1 SELP PF4 IGF1

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 VWF VEGFA TNNT2 TEK SERPINE1 SERPINC1
2 identical protein binding GO:0042802 9.92 VWF VEGFA TNNT2 TEK SERPINC1 HTR2A
3 cytokine activity GO:0005125 9.67 VEGFA PF4 IL6 IL10
4 heparin binding GO:0008201 9.43 VEGFA SERPINC1 SELP PGF PF4 F2
5 vascular endothelial growth factor receptor binding GO:0005172 9.26 VEGFA PGF
6 growth factor activity GO:0008083 9.1 VEGFA PGF IL6 IL10 IGF1 F2

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....